Avastin (bevacizumab)

P2, N=0, Withdrawn, Hoffmann-La Roche | N=164 --> 0 | Not yet recruiting --> Withdrawn

P2, N=206, Active, not recruiting, Fondazione Ricerca Traslazionale | Not yet recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> May 2027 | Trial primary completion date: May 2022 --> May 2027

P2, N=68, Not yet recruiting, The Fourth Affiliated Hospital of Zhejiang University School of Medicine

To the best of our knowledge, this is the first reported case of cecal NEC achieving pathological complete regression with a colorectal cancer-based chemotherapy regimen. Our findings indicate that colorectal NEC may respond not only to platinum-based regimens but also to colorectal cancer-based regimens. Furthermore, CEA levels may serve as a clinically relevant biomarker to guide chemotherapy selection in this setting.

We further report the development of engineered cell membrane vesicles encapsulating Bevacizumab, which are fused with TIGIT-expressing membranes and platelet membranes (referred to as Bev@TPNVs)...The intrahepatic metastasis burden is reduced by approximately 10-fold compared with the control group, and the survival rate of mice within 70 days reaches 50%. This work has the potential to establish a novel standard treatment paradigm that could revolutionize combined immunotherapy following liver metastasis ablation.

P2, N=120, Recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

P4, N=13, Completed, University Hospital, Rouen | Recruiting --> Completed | N=40 --> 13

P1/2, N=99, Not yet recruiting, Luye Pharma Group Ltd.

P2/3, N=120, Not yet recruiting, Nanjing Sanhome Pharmaceutical, Co., Ltd.

P2, N=35, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

In OC mice, TRIM28 overexpression promotes angiogenesis and Bev resistance via ESM1-mediated ITGB1/FAK activation. This work unveils a new molecular pathway underlying Bev resistance in OC and proposes TRIM28 and ESM1 as potential therapeutic targets.

Patients with non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations who experience disease progression after treatment with an EGFR-tyrosine kinase inhibitor (EGFR-TKI) often receive subsequent treatment with either platinum-based chemotherapy (Chemo) or a combination regimen of atezolizumab, bevacizumab, carboplatin, and paclitaxel (ABCP). After propensity score matching, among patients who responded to prior EGFR-TKIs for ≥10 months, the ABCP group had a significantly longer PFS than the Chemo group (8.6 versus 5.3 months; log-rank test, P = 0.008). The efficacy of prior EGFR-TKI treatment in patients with EGFR-mutant NSCLC who experience disease progression could be a predictive marker for ABCP rather than Chemo efficacy.